Abstract
To better understand COVID-19 pathobiology and to prioritize treatment targets, we sought to identify human genes influencing genetically driven disease risk and severity, and to identify additional organismal-level phenotypes impacted by pleiotropic COVID-19-associated genomic loci. To this end, we performed ancestry-aware, trans-layer, multi-omic analyses by integrating recent COVID-19 Host Genetics Initiative genome-wide association (GWAS) data from six ancestry endpoints - African, Amerindian, South Asian, East Asian, European and meta-ancestry - with quantitative trait loci (QTL) and GWAS endpoints by colocalization analyses. We identified colocalizations for 47 COVID-19 loci with 307 GWAS trait endpoints and observed a highly variable (1-435 endpoint colocalizations) degree of pleiotropy per COVID-19 locus but a high representation of pulmonary traits. For those, directionality of effect mapped to COVID-19 pathological alleles pinpoints to systematic protective effects for COPD, detrimental effects for lung adenocarcinoma, and locus-dependent effects for IPF. Among 64 QTL-COVID-19 colocalized loci, we identified associations with most reported (47/53) and half of unreported (19/38) COVID-19-associated loci, including 9 loci identified in non-European cohorts. We generated colocalization evidence metrics and visualization tools, and integrated pulmonary-specific QTL signal, to aid the identification of putative causal genes and pulmonary cells. For example, among likely causal genes not previously linked to COVID-19, we identified desmoplakin-driven IPF-shared genetic perturbations in alveolar cells. Altogether, we provide insights into COVID-19 biology by identifying molecular and phenotype links to the genetic architecture of COVID-19 risk and severity phenotypes; further characterizing previously reported loci and providing novel insights for uncharacterized loci.
Competing Interest Statement
MO, JR, RH, EK, BRG and JD are employees of AbbVie. JSL is an employee/Student of Northwestern University. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.
Funding Statement
The design, study conduct, and financial support for this research were provided by AbbVie.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data sets analyzed during the current study are available from the following repositories: summary statistics of the COVID-19 GWASs (round 7) by the COVID-19 Host Genetics Initiative are available at https://www.covid19hg.org/results/r7/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data sets analyzed during the current study are available from the following repositories: summary statistics of the COVID-19 GWASs (round 7) by the COVID-19 Host Genetics Initiative are available at https://www.covid19hg.org/results/r7/. The QTL summary statistics were obtained from multiple sources (see Methods). The variant calls from 1000 Genomes Project on the GRCh38 reference assembly are available from the UK Biobank Research Analysis Platform, accessible upon application approval. The summary statistics from the GWAS catalog are available at https://www.ebi.ac.uk/gwas/. Analysis and figures code, and figures data, has been deposited to https://github.com/AbbVie-ComputationalGenomics/COVID19_coloc_paper. R shiny is provided at https://covidgenes.shinyapps.io/shiny/ and https://github.com/AbbVie-ComputationalGenomics/COVID19_coloc_shiny
https://covidgenes.shinyapps.io/shiny/
https://github.com/AbbVie-ComputationalGenomics/COVID19_coloc_shiny
https://github.com/AbbVie-ComputationalGenomics/COVID19_coloc_paper
